BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

743 related articles for article (PubMed ID: 8363667)

  • 1. [Comparative study of HMB-45 monoclonal antibody uptake on various benign and malignant melanocytic lesions].
    Lampert A; Thomine E; Lauret P; Hemet J
    Ann Pathol; 1993; 13(2):100-7. PubMed ID: 8363667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
    Nasr MR; El-Zammar O
    Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic assessment of two novel proliferation-specific antigens in benign and malignant melanocytic lesions.
    Rudolph P; Lappe T; Schubert C; Schmidt D; Parwaresch RM; Christophers E
    Am J Pathol; 1995 Dec; 147(6):1615-25. PubMed ID: 7495287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of DNA ploidy and degree of DNA abnormality in benign and malignant melanocytic lesions of the skin using video imaging.
    Pilch H; Günzel S; Schäffer U; Tanner B; Heine M
    Cancer; 2000 Mar; 88(6):1370-7. PubMed ID: 10717619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Contribution of monoclonal antibody HMB45 in the histopathologic diagnosis of melanoma].
    Pluot M; Joundi A; Grosshans E
    Ann Dermatol Venereol; 1990; 117(10):691-9. PubMed ID: 1705764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fascin expression in melanocytic lesions of the skin.
    YILDIZ L; KEFELI M; AYDIN O; KANDEMIR B
    Eur J Dermatol; 2009; 19(5):445-50. PubMed ID: 19527987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
    Boyd AS; Shakhtour B; Shyr Y
    J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Unusual and unknown aspect of cutaneous malignant melanoma: minimal deviation malignant melanoma. Retrospective study of 45 cases].
    Mérot Y; Mihm MC
    Ann Dermatol Venereol; 1985; 112(4):325-36. PubMed ID: 4026131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Nevus associated malignant melanomas--diagnostic validation and prognosis].
    Stadler R; Garbe C
    Hautarzt; 1991 Jul; 42(7):424-9. PubMed ID: 1938395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immunohistochemical markers for cytoplasmic antigens in acquired melanosis, malignant melanomas, and nevi of the conjunctiva].
    Hitzer S; Bialasiewicz AA; Richard G
    Klin Monbl Augenheilkd; 1998 Oct; 213(4):230-7. PubMed ID: 9848068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas?
    Kaleem Z; Lind AC; Humphrey PA; Sueper RH; Swanson PE; Ritter JH; Wick MR
    Mod Pathol; 2000 Mar; 13(3):217-22. PubMed ID: 10757331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions.
    Massi D; Franchi A; Sardi I; Magnelli L; Paglierani M; Borgognoni L; Maria Reali U; Santucci M
    J Pathol; 2001 Jun; 194(2):194-200. PubMed ID: 11400148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simulators of malignant melanoma of the skin.
    Cerroni L; Kerl H
    Eur J Dermatol; 1998 Sep; 8(6):388-96. PubMed ID: 9729049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significant melanocytic lesions in infancy, childhood, and adolescence.
    Hoss DM; Grant-Kels JM
    Dermatol Clin; 1986 Jan; 4(1):29-44. PubMed ID: 3521978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distribution and colocalization of markers for proliferation, invasion, motility and neoangiogenesis in benign melanocytic naevi and malignant melanomas.
    Fröhlich E; Mack AF; Garbe C; Klessen C
    Br J Dermatol; 2005 Dec; 153(6):1159-65. PubMed ID: 16307652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Reactivity of five different antibodies with benign and malignant melanocytic lesions].
    Plótár V; Szentirmay Z; Orosz Z
    Magy Onkol; 2008 Dec; 52(4):363-73. PubMed ID: 19068464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality assessment by expert opinion in melanoma pathology: experience of the pathology panel of the Dutch Melanoma Working Party.
    Veenhuizen KC; De Wit PE; Mooi WJ; Scheffer E; Verbeek AL; Ruiter DJ
    J Pathol; 1997 Jul; 182(3):266-72. PubMed ID: 9349228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Distribution of melanoma-associated antigens (HMB 45 and S 100) in benign and malignant melanocytic tumors of the conjunctiva].
    Steuhl KP; Rohrbach JM; Knorr M
    Klin Monbl Augenheilkd; 1991 Sep; 199(3):187-91. PubMed ID: 1753671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. hTERT expression in melanocytic lesions: an immunohistochemical study on paraffin-embedded tissue.
    Fullen DR; Zhu W; Thomas D; Su LD
    J Cutan Pathol; 2005 Nov; 32(10):680-4. PubMed ID: 16293180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic and prognostic role of galectin 3 expression in cutaneous melanoma.
    Abdou AG; Hammam MA; Farargy SE; Farag AG; El Shafey EN; Farouk S; Elnaidany NF
    Am J Dermatopathol; 2010 Dec; 32(8):809-14. PubMed ID: 20885286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.